NCT05285839PHASE4Recruiting
Dupixent and Narrowband UVB for Atopic Dermatitis
Psoriasis Treatment Center of Central New Jersey
Start Date
4/19/2022
Completion Date
12/15/2024
Summary
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Detailed Description
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Male or female adult ≥ 18 years of age;
* Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
* EASI score of 16 or greater,
* IGA score of 3 or greater
* BSA of 10% or greater,
Exclusion Criteria:
* Subjects with previous exposure to dupilumab.
* Known or suspected hypersensitivity to dupilumab or any of its excipients.
* History of photosensitivity.
Interventions
DRUG
Dupixent
Conditions
Atopic Dermatitis
Locations
Eczema Treatment Center of New Jersey
East Windsor, New Jersey 08520
United States